Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows

Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows
Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological imaging — or death in metastatic hormone-sensitive prostate cancer (mHSPC) patients, a Phase 3 clinical trial shows. The benefits were seen independently of patients' initial PSA levels, suggesting that, contrary to prior beliefs, PSA levels are not an accurate predictive factor of responses to Xtandi in these patients. These findings were presented at the American Urological Association's 2019 Annual Meeting, held May 3–6 in Chicago, in a poster titled, “Efficacy of Androgen Deprivation Therapy with Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: Prostate-Specific Antigen Results.” Xtandi, developed by Pfizer and Astellas, is an approved treatment for men whose prostate cancer no longer responds to medical or surgical treatment that lowers testosterone, a condition called castration-resistant prostate cancer. Aiming to determine if the therapy also could be used in men with metastatic disease who responded to their last testosterone-lowering treatment, researchers designed the multinational ARCHES Phase 3 trial (
Subscribe or to access all post and page content.